Nabsys, a genomics company specializing in electronic genome mapping (EGM) technology, has made significant strides in the detection of repeat contraction and expansion disorders. In a recent collaboration with Leiden University Medical Center (LUMC), Nabsys is utilizing its OhmX Platform and EGM-based assay to study facioscapulohumeral muscular dystrophy (FSHD), a challenging disease to research using traditional methods. This partnership aims to accelerate the evaluation and validation of the assay, leveraging well-characterized reference samples and LUMC's expertise in FSHD research.
The collaboration was showcased at the European Society of Human Genetics (ESHG) 2026 Annual Meeting, where Nabsys presented data demonstrating the OhmX Platform's ability to detect repeat expansions in key genes associated with Fragile X syndrome and Friedreich's ataxia. By integrating CRISPR/Cas9 technology, the platform can accurately analyze samples that are difficult to assess using standard techniques.
Nabsys's OhmX Platform is a research-use-only EGM technology, offering high-resolution insights into genome structure. This technology has proven to be a reliable, simpler, and lower-risk alternative to other tools, making it accessible to laboratories worldwide. With its focus on accessibility and innovation, Nabsys aims to expand the reach of its OhmX Platform, delivering best-in-class genomic interrogation to researchers globally.
In my opinion, Nabsys's collaboration with LUMC and its advancements in EGM technology are groundbreaking. The company's ability to detect repeat expansions in challenging disorders like FSHD and its integration of CRISPR/Cas9 technology showcase its commitment to innovation. As an expert in the field, I believe that Nabsys's OhmX Platform has the potential to revolutionize genomic research, providing a more accessible and insightful tool for scientists worldwide.
Furthermore, Nabsys's focus on accessibility is commendable. By making its technology available to laboratories globally, the company is democratizing genomic research, allowing researchers of all sizes to benefit from its advancements. This approach not only accelerates scientific progress but also fosters a more inclusive and diverse research community.
In conclusion, Nabsys's collaboration with LUMC and its advancements in EGM technology are a testament to the company's commitment to innovation and accessibility. As an expert in the field, I am excited to see the impact of Nabsys's OhmX Platform on genomic research and its potential to transform the way we understand and treat genetic disorders.
